VivoSeq
Other

Organ Preservation

0

Pipeline Programs↗

7

Active Trials↗

1

Companies Involved↗

Organ Preservation is an early-stage landscape with 0 programs across 1 company. The most active players are Latin American Cooperative Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

L

Latin American Cooperative Oncology Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Recruiting4 · 40%
Completed3 · 30%
Active, not recruiting2 · 20%
Not yet recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)
Recruiting·—·Phase 2·NCT06991465·35 enrolled
Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
Recruiting·—·Phase 2·NCT06417476·66 enrolled
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
Recruiting·MMedical College of Wisconsin·Phase 1·NCT04808323·22 enrolled
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
Recruiting·UUniversity of Leipzig·Phase 2·NCT06137378·140 enrolled
Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
Active, not recruiting·LLatin American Cooperative Oncology Group·Phase 2·NCT04943445·43 enrolled
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
Active, not recruiting·Alliance for Clinical Trials in Oncology·Phase 2·NCT05610163·783 enrolled
Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT06504875·23 enrolled
Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT01633541·55 enrolled
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
Completed·SStanford University·Phase 2·NCT04380337·38 enrolled
Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA
Completed·KKing Faisal Specialist Hospital & Research Center·N/A·NCT00534729·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)